Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR): 18 pipeline candidates · 2 upcoming catalysts · ~16 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.1 months
0% dilution
Lead: Phase 3
18 candidates
2 upcoming, next in ~166d
N/A
A transparent, data-derived signal for Atea Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$346.5M
Cash
$79.3M
Quarterly Burn
$46.4M
Runway
16.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| at-587 | Preclinical |
| bemnifosbuvir | Phase 2 |
| Bemnifosbuvir-Ruzasvir | Phase 3 |
| Bemnifosbuvir/Ruzasvir | Phase 1 |
| bemnifosbuvir/ruzasvir + ethinyl estradioll/levonorgestrel | Phase 1 |
| bemnifosbuvir/ruzasvir as a fixed-dose combination | Phase 1 |
| Buprenorphine/Naloxone + BEM/RZR | Phase 1 |
| Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR | Phase 1 |
| Ethinyl Estradioll/Levonorgestrel | Phase 1 |
| Methadone +BEM/RZR | Phase 1 |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$281.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 11,950,772 | $64.3M |
| blackrock, inc. | 8,435,437 | $45.4M |
| vanguard capital management llc | 6,492,248 | $34.9M |
| tang capital management llc | 4,814,700 | $25.9M |
| two sigma investments, lp | 1,864,164 | $10.0M |
| geode capital management, llc | 1,747,706 | $9.4M |
| state street corp | 1,694,635 | $9.1M |
| dimensional fund advisors lp | 1,255,484 | $6.8M |
| rosalind advisors, inc. | 1,171,855 | $6.3M |
| renaissance technologies llc | 1,166,400 | $6.3M |
Showing top 10 of 125 institutional holders of Atea Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Atea Pharmaceuticals, Inc.'s pipeline?
Atea Pharmaceuticals, Inc. (AVIR) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Atea Pharmaceuticals, Inc.'s lead drug candidate?
Atea Pharmaceuticals, Inc.'s most advanced tracked candidate is at-587 (Preclinical) for chronic hepatitis E virus (HEV) infection in immunocompromised patients.
What is Atea Pharmaceuticals, Inc.'s next catalyst?
Atea Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvi" — expected December 1, 2026.
What is Atea Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Atea Pharmaceuticals, Inc. has approximately 16.1 months of cash runway.
What is Atea Pharmaceuticals, Inc.'s market capitalization?
Atea Pharmaceuticals, Inc.'s market capitalization is approximately $346.5M.
Get the full picture on Atea Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.